John Perkins, MD
Family Medicine · Elk City, OKNPI 1437141983
Payments from drug & device makers
Across 115 payments — averaging $15.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$402
- Johnson & Johnson$274
- Amgen$183
- Novo Nordisk$91
- IBSA Pharma Inc.$88
- Axsome Therapeutics, Inc.$82
- plus $648 from 20 others
What the payments were for
- Food & beverage$1,75799%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 45 | $402 |
| Johnson & Johnson | 9 | $274 |
| Amgen | 12 | $183 |
| Novo Nordisk | 2 | $91 |
| IBSA Pharma Inc. | 5 | $88 |
| Axsome Therapeutics, Inc. | 2 | $82 |
| GSK | 5 | $77 |
| AstraZeneca | 2 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $67 |
| Antares Pharma, Inc. | 3 | $63 |
| Lilly USA, LLC | 4 | $51 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $51 |
| Biohaven Pharmaceuticals, Inc. | 3 | $35 |
| Halozyme Inc | 2 | $30 |
| Dexcom, Inc. | 2 | $27 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $20 |
| Novartis | 1 | $19 |
| Si-bone, Inc. | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Merck | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| AbbVie | 1 | $13 |
| Eisai Inc. | 1 | $13 |
| Tosoh Bioscience, Inc. | 1 | $10 |
How this compares
$1,769 in reported general payments places this provider in the 70th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 149 | $157,047 |
| OzempicSemaglutide | 130 | $132,532 |
| EliquisApixaban | 142 | $91,548 |
| Humira(Cf)Adalimumab | 12 | $77,755 |
| RybelsusSemaglutide | 57 | $56,255 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 77 | $52,504 |
| TrulicityDulaglutide | 33 | $39,530 |
| XareltoRivaroxaban | 33 | $28,350 |
| Aimovig AutoinjectorErenumab-Aooe | 37 | $25,722 |
| XyostedTestosterone Enanthate | 38 | $23,533 |
| TrintellixVortioxetine Hydrobromide | 42 | $21,792 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $17,667 |
| Emgality PenGalcanezumab-Gnlm | 19 | $14,590 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $14,315 |
| JanuviaSitagliptin Phosphate | 13 | $13,655 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $51 | $196,577182 claims |
| Novo NordiskOzempic, Rybelsus | $91 | $188,787187 claims |
| PfizerEliquis, Abrysvo, Premarin | $402 | $106,427182 claims |
| AbbVieHumira(Cf), Ubrelvy, Linzess, Synthroid | $13 | $102,843112 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $77 | $62,701115 claims |
| Johnson & JohnsonXarelto | $274 | $28,35033 claims |
| Antares Pharma, Inc.Xyosted | $63 | $23,53338 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $67 | $21,79242 claims |
| AstraZenecaBreztri Aerosphere, Qtern | $67 | $21,14133 claims |
| MerckJanuvia, Belsomra | $15 | $18,65925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Elk City
- Michael RobinsonElk City$84K
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.